Fact checked byMindy Valcarcel, MS

Read more

July 24, 2022
1 min read
Save

MD Anderson appoints division head of pathology and laboratory medicine

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Donna Hansel, MD, PhD, has been named division head of pathology and laboratory medicine at The University of Texas MD Anderson Cancer Center.

Hansel’s appointment will take effect Sept. 12.

The division provides patient data to guide clinical care, manages transfusions and blood products for hundreds of patients each day, and conducts multidisciplinary research.

Donna Hansel, MD, PhD
Donna Hansel

Hansel will lead a team of 650 people, including 130 research and clinical faculty.

“We are pleased for Dr. Hansel to join MD Anderson and to share her wealth of experience with our community,” Peter WT Pisters, MD, president of MD Anderson, said in a press release. “She is an exceptional leader with strong academic and professional skills, and she is a model of our core values — all essential traits that will serve her and our institution well as she leads this critical team.”

Hansel currently serves as professor and chair of pathology and laboratory medicine at Oregon Health & Science University. She previously has served on the faculty at Cleveland Clinic and University of California, San Diego.

She has subspecialty clinical expertise in urologic pathology, including bladder, kidney, prostate and testicular cancers.

“I am thrilled to join MD Anderson as division head of pathology and laboratory medicine,” Hansel said in the release. “It is truly an honor to have the opportunity to work with so many outstanding faculty, trainees and staff within the division and across the institution. I look forward to supporting excellence in the division and to growing innovative new programs to advance our efforts to eliminate cancer.”